US stocks surged | positive data from Phase 1 SENTI-202 trial Senti Biosciences(SNTI.US) rose more than 7% at the opening bell.

According to the Zhuotong Financial APP, on Tuesday, Senti Biosciences (SNTI.US) opened up more than 7%, reaching $2.54. In terms of news, Senti Bio reported updated data from Phase 1 of SENTI-202 in R/R AML, showing a 50% overall response rate (ORR), 42% complete response/partial hematologic response (CR/CRh), with the majority achieving a durable response with minimal residual disease negativity (MRD-Negative), and receiving RMAT support to advance to pivotal studies.